Vertaling van "have another look at " (Nederlands → Frans) :

Imperfect though it may be, it was interesting to have another look at Baechler’s definition that treats suicide as all behaviour that seeks and finds the solution to an existential problem by making an attempt on the life of the subject. There were several reasons for this:
Malgré les imperfections possibles de la définition de Baechler qui parle du suicide comme tout comportement qui cherche et qui trouve la solution d’un problème existentiel dans le fait d’attenter à la vie du sujet, il était intéressant de la reprendre et cela pour plusieurs raisons:

We will not dwell on the other definitions of suicide that have been provided by these different disciplines, but will look at one, viz. the one given by Baechler (Baechler, 1975), which goes as follows: “Suicide denotes all behaviour that seeks and finds the solution to an existential problem by making an attempt on the life of the subject”.
Mais nous en retiendrons une, celle de Baechler (Baechler, 1975): « le suicide désigne tout comportement qui cherche et qui trouve la solution d’un problème existentiel dans le fait d’attenter à la vie du sujet ».

patients has to do with the fact that on the one hand, psychological suffering is less tangible than somatic suffering and that, on the other hand, any injuries that need looking after have been caused by the patients themselves.
certain malaise face à ces patients tient au fait que, d’une part, la souffrance psychique est moins tangible que la souffrance somatique et que, d’autre part, les éventuelles lésions à soigner ont été provoquées par le patient lui-même.

The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians
The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians

Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated. In addition to these 74 indicators, 11 indicators for which data are expected
Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.